-

Altasciences Receives Accreditation From College of American Pathologists

LAVAL, Québec--(BUSINESS WIRE)--The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Altasciences’ clinical site in Los Angeles, California, based on results of a recent on-site inspection.

Altasciences was advised of this national recognition and congratulated for the excellence of the services being provided. Altasciences’ Los Angeles site is one of more than 8,000 CAP-accredited facilities worldwide.

“This prestigious accreditation is a testament to the high-quality work and oversight by Altasciences’ dedicated and passionate team in Los Angeles. We are pleased to give our clients the peace of mind that comes with working with a CAP-accredited biorepository, and are proud to have a seal of approval that reflects the quality of our work,” stated Dr. David Nguyen, General Manager and Medical Director at Altasciences’ Los Angeles site.

The CAP, first in the industry to offer an accreditation program for biorepositories, based the Biorepository Accreditation Program on the principles of its Laboratory Accreditation Program. The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to, or more stringent than, the government’s own inspection program. Currently, there is no federal mandate for biorepository accreditation.

The CAP Biorepository Accreditation Program, a three-year accreditation cycle, includes on-site inspection, desk review, and optional education modules and gap assessment. As part of the on-site inspection, the CAP uses accreditation checklists to provide a comprehensive, up-to-date blueprint of quality practices to assist biorepositories in improving their operations and ensure quality. Further, a desk review offers a remote review of a biorepository’s quality management plan, certain procedures, and select quality and process statistics. The program is designed to ensure the highest standard of patient care.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing program, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP ANNUAL REPORT at cap.org.

Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

Altasciences

Details
Headquarters: Laval, Canada
CEO: Marie-Hélène Raigneau
Employees: 2,000+
Organization: PRI


Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

Social Media Profiles
More News From Altasciences

Altasciences Continues to Expand North American Bioanalytical Footprint

LAVAL, Québec--(BUSINESS WIRE)--Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a n...

Altasciences Completes Expansion of Research and Development Laboratory in Harleysville, Pennsylvania

LAVAL, Québec--(BUSINESS WIRE)--Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space. The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scient...

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in...
Back to Newsroom